|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 22718 |
FusionGeneSummary for MTCH1_C3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MTCH1_C3 | Fusion gene ID: 22718 | Hgene | Tgene | Gene symbol | MTCH1 | C3 | Gene ID | 23787 | 718 |
| Gene name | mitochondrial carrier 1 | complement C3 | |
| Synonyms | CGI-64|PIG60|PSAP|SLC25A49 | AHUS5|ARMD9|ASP|C3a|C3b|CPAMD1|HEL-S-62p | |
| Cytomap | 6p21.2 | 19p13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | mitochondrial carrier homolog 1cell proliferation-inducing protein 60presenilin-associated proteinsolute carrier family 25, member 49 | complement C3C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1C3a anaphylatoxinacylation-stimulating protein cleavage productcomplement component 3complement component C3acomplement component C3bepididymis secretory sperm binding pr | |
| Modification date | 20180523 | 20180519 | |
| UniProtAcc | Q9NZJ7 | P01024 | |
| Ensembl transtripts involved in fusion gene | ENST00000373627, ENST00000373616, ENST00000471737, ENST00000538808, | ENST00000245907, ENST00000599668, | |
| Fusion gene scores | * DoF score | 4 X 5 X 1=20 | 14 X 13 X 6=1092 |
| # samples | 5 | 14 | |
| ** MAII score | log2(5/20*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(14/1092*10)=-2.96347412397489 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: MTCH1 [Title/Abstract] AND C3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | C3 | GO:0001934 | positive regulation of protein phosphorylation | 15833747 |
| Tgene | C3 | GO:0010575 | positive regulation of vascular endothelial growth factor production | 16452172 |
| Tgene | C3 | GO:0010828 | positive regulation of glucose transmembrane transport | 9059512|15833747 |
| Tgene | C3 | GO:0010866 | regulation of triglyceride biosynthetic process | 10432298 |
| Tgene | C3 | GO:0010884 | positive regulation of lipid storage | 9555951 |
| Tgene | C3 | GO:0045745 | positive regulation of G-protein coupled receptor protein signaling pathway | 15833747 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AA169517 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000373627 | ENST00000245907 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-intron | ENST00000373627 | ENST00000599668 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-3CDS | ENST00000373616 | ENST00000245907 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-intron | ENST00000373616 | ENST00000599668 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-3CDS | ENST00000471737 | ENST00000245907 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-intron | ENST00000471737 | ENST00000599668 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-3CDS | ENST00000538808 | ENST00000245907 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
| intron-intron | ENST00000538808 | ENST00000599668 | MTCH1 | chr6 | 36949310 | - | C3 | chr19 | 6684452 | - |
Top |
FusionProtFeatures for MTCH1_C3 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MTCH1 | C3 |
| C3 plays a central role in the activation of thecomplement system. Its processing by C3 convertase is the centralreaction in both classical and alternative complement pathways.After activation C3b can bind covalently, via its reactivethioester, to cell surface carbohydrates or immune aggregates. Derived from proteolytic degradation of complement C3,C3a anaphylatoxin is a mediator of local inflammatory process. Inchronic inflammation, acts as a chemoattractant for neutrophils(By similarity). It induces the contraction of smooth muscle,increases vascular permeability and causes histamine release frommast cells and basophilic leukocytes. {ECO:0000250}. C3-beta-c: Acts as a chemoattractant for neutrophils inchronic inflammation. {ECO:0000250}. Acylation stimulating protein: adipogenic hormone thatstimulates triglyceride (TG) synthesis and glucose transport inadipocytes, regulating fat storage and playing a role inpostprandial TG clearance. Appears to stimulate TG synthesis viaactivation of the PLC, MAPK and AKT signaling pathways. Ligand forC5AR2. Promotes the phosphorylation, ARRB2-mediatedinternalization and recycling of C5AR2 (PubMed:8376604,PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747,PubMed:16333141, PubMed:19615750). {ECO:0000269|PubMed:10432298,ECO:0000269|PubMed:15833747, ECO:0000269|PubMed:16333141,ECO:0000269|PubMed:19615750, ECO:0000269|PubMed:2909530,ECO:0000269|PubMed:8376604, ECO:0000269|PubMed:9059512}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for MTCH1_C3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for MTCH1_C3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for MTCH1_C3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | C3 | P01024 | DB01593 | Zinc | Complement C3 | small molecule | approved|investigational |
Top |
RelatedDiseases for MTCH1_C3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | C3 | C0242383 | Age related macular degeneration | 4 | CTD_human |
| Tgene | C3 | C2752037 | HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5 | 2 | ORPHANET;UNIPROT |
| Tgene | C3 | C3151071 | COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE | 2 | ORPHANET;UNIPROT |
| Tgene | C3 | C0007787 | Transient Ischemic Attack | 1 | CTD_human |
| Tgene | C3 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
| Tgene | C3 | C0017665 | Membranous glomerulonephritis | 1 | CTD_human |
| Tgene | C3 | C0021051 | Immunologic Deficiency Syndromes | 1 | CTD_human |
| Tgene | C3 | C0021655 | Insulin Resistance | 1 | CTD_human |
| Tgene | C3 | C0030524 | Paratuberculosis | 1 | CTD_human |
| Tgene | C3 | C0030807 | Pemphigus | 1 | CTD_human |
| Tgene | C3 | C0034152 | Henoch-Schoenlein Purpura | 1 | CTD_human |
| Tgene | C3 | C0740392 | Infarction, Middle Cerebral Artery | 1 | CTD_human |
| Tgene | C3 | C1969651 | Macular Degeneration, Age-Related, 9 | 1 | CTD_human;UNIPROT |
| Tgene | C3 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|